ciltacabtagene autoleucel - Medications
Browse 1 medications containing ciltacabtagene autoleucel. Open a product record to review formulation details, related brands, manufacturers, and label-backed information.
CARVYKTI ® (ciltacabtagene autoleucel) is a BCMA-directed genetically modified autologous T cell immunotherapy. CARVYKTI is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure. The mononuclear cells are enriched for T cells and genetically modified ex vivo by transduction with a replication-incompetent lentiviral vector to express a CAR comprising an anti-BCMA targeting domain, which consists of two single-domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. The transduced anti-BCMA CAR T cells are expanded in cell culture, washed, formulated into a suspension and cryopreserved. The product must pass a sterility test before release for shipping as a frozen suspension in a patient-specific infusion bag. The product is thawed and then infused back into the patient, where the anti-BCMA CAR T cells can recognize and eliminate BCMA-expressing target cells [see Dosage and Administration (2.2) , How Supplied/Storage and Handling (16) ]. In addition to T cells, CARVYKTI may contain Natural Killer (NK) cells. The formulation contains 5% dimethyl sulfoxide (DMSO).
About ciltacabtagene autoleucel
This collection groups medications in our database that include ciltacabtagene autoleucel. It currently includes 1 matching listing.
What You Can Review
Use this page to find products that share the same indexed ingredient name, then open drug detail pages for dosage, labeling, and related navigation.
Safety Information
Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. The information provided on this page is for educational purposes only and does not constitute medical advice.